Related Experiment Videos
Beta-thromboglobulin levels in the nephrotic syndrome
The American Journal of Medicine
|October 1, 1980
Summary
Patients with nephrotic syndrome show elevated beta-thromboglobulin (BTG) levels, indicating increased platelet aggregation. BTG concentrations normalized in patients whose nephrotic syndrome went into remission, suggesting a link to hypercoagulability.
Area of Science:
- Nephrology
- Hematology
- Clinical Biochemistry
Background:
- Nephrotic syndrome is a complex kidney disorder.
- Platelet activation and aggregation play roles in various pathological conditions.
- Beta-thromboglobulin (BTG) is a marker of platelet activation.
Purpose of the Study:
- To investigate the levels of beta-thromboglobulin (BTG) in patients with nephrotic syndrome.
- To explore the potential association between BTG levels and the hypercoagulable state in nephrotic syndrome.
Main Methods:
- Measurement of serum beta-thromboglobulin (BTG) concentrations.
- Comparison of BTG levels in patients with nephrotic syndrome, normal controls, and non-nephrotic azotemic patients.
- Monitoring BTG levels in patients with nephrotic syndrome during remission.
Main Results:
- All 13 patients with nephrotic syndrome exhibited significantly higher BTG concentrations compared to controls (p < 0.001).
- BTG levels in nephrotic patients were also elevated compared to non-nephrotic azotemic individuals.
- In five patients who achieved remission from nephrotic syndrome, BTG levels returned to normal.
Conclusions:
- The nephrotic syndrome is associated with a state of hypercoagulability.
- Increased platelet aggregation is a potential primary mechanism underlying this hypercoagulability.
- BTG may serve as a useful biomarker for assessing platelet activation in nephrotic syndrome.